Drug Information

Drug (ID: DG01692) and It's Reported Resistant Information

• Name: Alpelisib/Fulvestrant
• Synonyms: Alpelisib/Fulvestrant
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.C420R (c.1258T>C)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E542K (c.1624G>A)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E545K (c.1633G>A)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E545A (c.1634A>C)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E545G (c.1634A>G)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E545D (c.1635G>C)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.Q546E (c.1636C>G)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.Q546R (c.1637A>G)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.H1047Y (c.3139C>T)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.H1047R (c.3140A>G)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.H1047L (c.3140A>T)
• Sensitive Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Experimental Note: Identified from the Human Clinical Data

References

• Ref 1: Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast CancerN Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.